Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04330456
Other study ID # SaE in STS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2020
Est. completion date July 1, 2028

Study information

Verified date February 2020
Source N.N. Petrov National Medical Research Center of Oncology
Contact Grigory Zinovev, PhD
Phone +79213405814
Email zinovevgrigory@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Combined treatment of soft tissue sarcoma includes 3 steps:

1. step - preoperative stereotactic radiation therapy in hypofractionation mode

2. step - operation

3. step - postoperative conformal radiation therapy in normofractionation mode


Description:

Combined treatment of soft tissue sarcoma includes 3 steps:

1. At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues.

At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation.

GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy.

2. Second step is surgery in 14-21 days.

3. In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) СTV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm.

PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 1, 2028
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- morphologically verified diagnosis of soft tissue sarcoma

- first diagnosed tumor process

- ability to perform radical surgery

- signed informed consent

- indications for stereotactic and conformal radiation therapy

- no contraindications for radiation and surgical treatment

Exclusion Criteria:

- previous radiation treatment

- acute infection

- pregnancy, lactation

- recurrent tumor

- refuse to sign informed consent

- conditions that can affect the outcome of treatment (immunodeficiency, tuberculosis, etc.)

- tumor topography and volume that don't allow to perform stereotactic and conformal radiation therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Preoperative stereotactic radiation therapy in hypofractionation mode
At the first step patient undergoes preoperative stereotactic radiation therapy in hypofractionation mode. Radiation therapy plan is based on topometric MRI and CT scans. Radiation therapy plan are performed after MRI and CT fusion, contouring of the target and surrounding normal tissues. At first step only tumor and, if necessary, the surrounding normal tissues, which will be removed during surgery, are exposed to radiation. GTV - determined in with the boundaries of the tumor visualised by topometric MRI and CT CTV1 - match GTV CTV2 - formed inward (to the tumor center) from GTV by 0.5-1 cm (depending on the proximity of functionally significant normal tissues (neurovascular bundles, bone tissue, skin and subcutaneous fat, etc.) PTV - 3-5 mm indent from CTV1, taking into account the proximity of functionally significant normal tissues and the planned surgery Preoperative radiation therapy is carried in 5 fractions with a single dose on PTV - 5 Gy, a single dose on CTV2 - 7 Gy.
Procedure:
Surgery
In 14-21 days after preoperative stereotactic radiation therapy radical surgery will be performed
Radiation:
Postoperative conformal radiation therapy in normofractionation mode
In 25-35 days after the surgery postoperative conformal radiation therapy is performed according to the standard protocol GTV (tumor bed) - based on the volume of the primary tumor, including the swelling zone (T2-weighted images on preoperative MRI) ?TV - formed with an indent of 4 cm from GTV (without going beyond the boundaries of the involved compartment), in the transverse direction the indent could be reduced to 2 cm. PTV - formed with an indent of 0.5-1cm from CTV An important condition for planning radiation therapy is to limit the dose absorbed during both stages of radiation therapy in surrounding normal tissues that are not removed during surgery.

Locations

Country Name City State
Russian Federation National Research Center of Oncology named after N.N.Petrov Saint Petersburg

Sponsors (1)

Lead Sponsor Collaborator
N.N. Petrov National Medical Research Center of Oncology

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complications Rate of complications will be measured after completing each step of protocol: stereotactic radiation therapy, surgery and them postoperative conformal radiation therapy 3 year
Secondary Disease-Free survival Disease-Free survival will be evaluated after completing the protocol or during the protocol if local recurrence will appear. 3 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04656262 - Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients Phase 3
Recruiting NCT03077178 - Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over N/A
Not yet recruiting NCT06110650 - A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma N/A
Terminated NCT03735758 - Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib Phase 4
Not yet recruiting NCT03951571 - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma Phase 2
Enrolling by invitation NCT03134742 - Radiation Effects on Bone
Not yet recruiting NCT06252727 - Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) Phase 1
Recruiting NCT04617327 - Pre-operative RadiothErapy for Soft Tissue SarcOmas N/A
Recruiting NCT06385288 - Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas N/A
Recruiting NCT05116254 - Sarcomas and DDR-Inhibition; a Combined Modality Study Phase 1
Active, not recruiting NCT03526679 - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04008238 - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients N/A
Recruiting NCT04095208 - Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Phase 2
Completed NCT03833037 - Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
Completed NCT03056599 - Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Phase 1
Recruiting NCT05961761 - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Phase 2
Recruiting NCT06273852 - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors Early Phase 1
Recruiting NCT05182164 - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Phase 2
Withdrawn NCT03104335 - Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial Phase 2